The review found no eligible studies for this question.
It is very uncertain whether multi‐component interventions (with telehealth as a component of care) changes adverse events: number of people with 1 or more (all‐cause) compared with usual care (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Omalizumab showed no clear difference in adverse events compared with usual care (moderate certainty).
A boost of inhaled corticosteroids showed no clear difference in adverse events compared with usual care (moderate certainty).
Leukotriene receptor antagonist showed no clear difference in adverse events compared with usual care (high certainty).
The review found no eligible studies for this question.
Simplified showed no clear difference in all adverse events compared with usual regimens (low certainty).
Testosterone therapy showed no clear difference in adverse events (all cause) compared with placebo (low certainty).
It is very uncertain whether multi‐component intervention changes adverse events: number of people experiencing an AE compared with other intervention or routine, usual care or control treatment (very low certainty).
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing a serious adverse event compared with other intervention or routine, usual care or control treatment (low certainty).
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing adverse events (all… compared with control (low certainty).
It is very uncertain whether single component intervention changes adverse events: number of people experiencing adverse events (all… compared with control (very low certainty).